Evaluation of Serum Vascular Adhesion Protein-1 as a Potential Biomarker in Thyroid Cancer

Hu, Zhigang; Zhao, Pengxin; Zhang, Kaili; Zang, Leilei; Liao, Haiying; Ma, Wenxue

doi:10.1155/2016/6312529

Cited by 11 publications

(6 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The optimal cutoff value of VAP-1 for diagnosis of thyroid cancer was 456.6ng/mL, with a specificity of 77.4% and a sensitivity of 66.7%. 58 Meanwhile, Baki’s research in 2019 also confirmed its value as a potential marker. 59…”

Section: Blood Markersmentioning

confidence: 97%

<p>The Blood Biomarkers of Thyroid Cancer</p>

Wang¹,

Chang²,

Jia³

et al. 2020

CMAR

View full text Add to dashboard Cite

Introduction: With the gradual increase in the incidence of thyroid cancer, people's attention to thyroid cancer has also gradually increased. Although the prognosis of thyroid cancer is rather mild compared to other cancers, it will still bring a heavy psychological burden on people who have been diagnosed. At present, the diagnosis of thyroid cancer mainly depends on ultrasound and percutaneous fine needle aspiration (pFNA). Due to the unsatisfactory accuracy of the diagnosis methods we use now, there are still some thyroid nodules that cannot be clearly diagnosed before surgery. Methods: In this article, we have searched for relevant research on blood markers of thyroid cancer in the past five years and categoried them into four groups. Discussion: Though we have not found a biomarker which can diagnose thyroid cancer both sensitively and specifically, we do found many substances that are related to it, and have the potential to recognize it and help the diagnosis. And perhaps combined models can do it better.

show abstract

Section: Blood Markersmentioning

confidence: 97%

<p>The Blood Biomarkers of Thyroid Cancer</p>

Wang¹,

Chang²,

Jia³

et al. 2020

CMAR

View full text Add to dashboard Cite

show abstract

“…Hu et al (28) find that serum VAP-1 levels are significantly lower in thyroid cancer group than in healthy control and benign thyroid nodule groups. Another important finding of their study is that serum VAP-1 has relatively high sensitivity and specificity in predicting thyroid cancer.…”

Section: Discussionmentioning

confidence: 98%

Can VAP-1 Protein be used as a Biomarker in Thyroid Cancer?

Baki¹,

Tosun²,

Yıldız³

2019

Istanbul Med J

View full text Add to dashboard Cite

Results: In our study, 13 papillary carcinoma tissues, five follicular carcinoma tissues, six benign nodules, and one healthy tissue were stained positively. Although there was a statistically significant difference between papillary carcinoma and healthy tissue, no statistically significant difference was found between the other groups. Conclusion: VAP-1 glycoprotein can be used as a biomarker in the diagnosis of papillary thyroid carcinoma.

show abstract

“…A relationship with malignancy was found if the level of midline pleotropic growth factor used to distinguish benign and malignant nodu les was higher than 323.12 pg/mL, its sensitivity, specificity, and diagnostic accuracy rates of 75.70, 75.00, and 75.31 %, respectively [21]. In another study performed with vascular adhesion protein-1 (VAP-1), the cutoff was found to be 456.6 ng/mL and it was found that the VAP-1 level was lower in patients with thyroid cancer than in healthy individuals without benign nodules with a specificity of 77.4 % and a sensitivity of 66.7 % respectively [22].…”

Section: Discussionmentioning

confidence: 99%

“…In colon cancer and in breast cancer WISP1 is upregulated in CAFs more than in fibroblasts at the adjacent normal tissue [36,37]. In many cancers WISP1 is accumulated in the tumor stroma which around the cancer cells [22,[36][37][38][39]. In an experimental animal study, it has been shown that serum and tissue WISP1 levels are high in the early stages of prostate cancer, and the severity of the disease increases with the decrease in tissue and serum WISP1 levels.…”

Section: Discussionmentioning

confidence: 99%

Serum WNT-induced secreted protein 1 level as a potential biomarker for thyroid nodules

Duman

Sariakçali

2021

Mìžnarodnij endokrinologìčnij žurnal

View full text Add to dashboard Cite

Background. Thyroid nodule (TN) is a common thyroid disease worldwide, and it has increased significantly last decades. Most TNs are usually incidental findings of asymptomatic, benign lesions discovered by imaging modalities performed for reasons unrelated to thyroid diseases. The purpose of this study was to investigate the value of serum WNT-induced secreted protein 1 (WISP1) level as a supporting biomarker to perform differential diagnosis of benign and non-benign thyroid nodules. Materials and methods. The study was completed with the 89 patients undergone fine needle aspiration biopsy and 43 controls. The patients were composed of 96 (72.7 %) females and 36 (27.3 %) males. And they were divided into 2 group according to the Bethesda cytological evaluation as Benign (Bethesda 2) and Non-Benign (Bethesda 3–6) groups. Their serum WISP1 levels were measured by an ELISA method. Results. There were 58 (43.9 %) patients in Benign (Bethesda 2) and 31 (23.5 %) in non-Benign (Bethesda 3–6) groups. In the contrary nodule size was bigger in the Non-benign group than that benign group (p = 0.006). The serum WISP1 level in the Benign (Bethesda 2) group was significantly higher than that in the and Non-Benign (Bethesda 3–6) group, and controls (p < 0). The difference between benign and non-benign group accordingly to their echogenicitiy was significant (p < 0.05). In benign group there was 76.9 % mixed echoic nodules, 76.7 % isoechoic nodules 68.4 % isohypoechoic nodules and 35.7 % hypoechoic nodules. In the non-benign group, the highest hypoechoic echo (64.3 %), the least mixed echo (23.1 %), while in the benign group, the most mixed echo (76.9 %), the least hypoechoic echo (35.7 %) was present. There was no relation between WISP1 levels and echogenicity with Kruskal-Wallis H test. Conclusions. According to the preliminary results of current study, addition of serum WISP1 measurement to the differential diagnostic work-up of thyroid nodules patients may provide supportive information. In thyroid nodules patients with Benign (Bethesda 2) category of cytological evaluation, a higher level of serum WISP1 may support cytological diagnosis.

show abstract

Evaluation of Serum Vascular Adhesion Protein-1 as a Potential Biomarker in Thyroid Cancer

Cited by 11 publications

References 48 publications

<p>The Blood Biomarkers of Thyroid Cancer</p>

<p>The Blood Biomarkers of Thyroid Cancer</p>

Can VAP-1 Protein be used as a Biomarker in Thyroid Cancer?

Serum WNT-induced secreted protein 1 level as a potential biomarker for thyroid nodules

Contact Info

Product

Resources

About